Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer (EOC)

Slaughter, Katrina

431 - Poster Session B
Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer (EOC)

Sunday, March 23, 2014: 1:00 PM

West Exhibit Hall (Tampa Convention Center)

K. N. Slaughter¹, T. Thai², S. Penaroza², D. M. Benbrook², E. Thavathiro², K. Ding¹, D. S. McMeekin¹ and K. N. Moore¹
¹The University of Oklahoma, Oklahoma City, OK, ²The University of Oklahoma Health Sciences Center, Oklahoma City, OK

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

431 - Poster Session B
Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer (EOC)

431 - Poster Session B Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer (EOC)

431 - Poster Session B
Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer (EOC)